Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.80 |
| ▸ | CA1 | P00915 | 3/20 | 0.80 |
| ▸ | CA9 | Q16790 | 3/20 | 0.80 |
| ▸ | CA12 | O43570 | 2/20 | 0.80 |
| ▸ | CA3 | P07451 | 1/20 | 0.80 |
| ▸ | CA4 | P22748 | 1/20 | 0.80 |
| ▸ | CA6 | P23280 | 1/20 | 0.80 |
| ▸ | CA5A | P35218 | 1/20 | 0.80 |
| ▸ | CA7 | P43166 | 1/20 | 0.80 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.80 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.80 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526906 | 0.89 | CA2 (1.00) | CA2CA1CA9CA12CA3 | |
| SCHEMBL620638 | 0.87 | CA1 (0.60) | CA2CA1CA9CA12CA3 | |
| SCHEMBL17907417 | 0.86 | SMN1; SMN2 (1.00) | CA2CA1CA9CA12CA3 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL8934595 | 0.82 | HSPB1 (0.76) | CA2CA1CA9SMN1; SMN2LMNA | |
| SCHEMBL177792 | 0.81 | HSPB1 (0.59) | CA2CA1CA9CA12CA3 | |
| SCHEMBL11846940 | 0.80 | SMN1; SMN2 (0.64) | CA2CA1CA9CA12CA3 | |
| SCHEMBL9852534 | 0.80 | SMN1; SMN2 (0.64) | CA2CA1CA9CA12CA3 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL134332 | 0.80 | HSPB1 (0.79) | CA2CA1CA9SMN1; SMN2LMNA | |
| SCHEMBL11689190 | 0.80 | HSPB1 (0.79) | CA2CA1CA9SMN1; SMN2LMNA | |
| SCHEMBL9183872 | 0.80 | HSPB1 (0.79) | CA2CA1CA9SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| CN-1341098-A | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER AG (US) | 2002-03-20 | — | — | CN | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CA2 4539/4885CA1 4830/4885CA9 4490/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | CA2 3850/4885CA1 4687/4885CA9 3181/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CA2 4543/4885CA1 4853/4885CA9 4638/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CA2 4543/4885CA1 4853/4885CA9 4638/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CA2 4253/4885CA1 4792/4885CA9 4459/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | CA2 4564/4885CA1 4862/4885CA9 4489/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | CA2 4527/4885CA1 4850/4885CA9 4626/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CA2 4543/4885CA1 4853/4885CA9 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.